Efficacy and safety benefits of <scp>HR17031</scp> , a fixed‐ratio combination of <scp>INS068</scp> and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open‐label, randomised, parallel three‐arm, treat‐to‐target trial
Linong Ji(Peking University), Zi Ye(Jiangsu Hengrui Medicine (China)), Quanren Wang(Jiangsu Hengrui Medicine (China)), Li Mao(Nanjing University of Chinese Medicine), Xiang Lin(Jiangsu Hengrui Medicine (China)), Qing‐Yuan Sun(Jinan University), Xiaodong Sun(Weifang Medical University), Li Lü(Tongji Hospital)
Cited by 1
Related Papers
Prevalence of Diabetes among Men and Women in China
|New England Journal of Medicine|2010|3.1k
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
|JAMA Oncology|2019|694
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
|Nature Genetics|1995|646
Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I
|Nature Cell Biology|1999|491